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Summary The deuterated benzaldehyde derivative zilascorb(QH), 5,6-O-benzylidene-d-L-ascorbic acid, was
administered once daily by i.v. injection in nude mice with grafted tumours of a human malignant melanoma
(E.E.) and ovarian carcinoma (OVCAR-3) origins. Like benzaldehyde, zilascorb(2H) has been shown to induce
protein synthesis inhibition at otherwise non-toxic doses in cells grown in vitro, and acts reversibly in the sense
that protein synthesis returns to normal shortly after removal of the drug. The present data indicate that daily
injections with zilascorb(2H) induce a tumour volume growth inhibitory effect in both tumour xenografts
studied. Furthermore, from histological examinations of each single tumour it was found that tumours of
drug-treated animals, although smaller than those of placebo-treated (i.e. control) animals, had, on average, a
higher necrotic fraction than control tumours. Thus, it is concluded that zilascorb(2H) induces tumour
necrotisation and not just inhibition of the rate of tumour cell production. Continued measurement of tumour
volume after ended treatment with zilascorb(2H) indicated that surviving tumour cells resumed their normal
growth rate immediately. The reversibility of the effect induced by this compound, earlier observed in vitro
only, is therefore here confirmed to be valid also in two different tumour xenografts in vivo. The present data
accords well with the assumption that protein synthesis inhibition is the primary cellular effect ofzilascorb(2H)
in vivo. We therefore conclude that zilascorb(2H)-induced cancer cell lethality in tumour xenografts probably
comes as a secondary consequence of prolonged protein synthesis inhibition.
In many frequently occurring cancer types prognosis has not
improved following chemotherapy in the way that many
clinicians hoped for just two decades ago (Cairris, 1985;
Corbett et al., 1987). Although new ways ofcombining estab-
lished cancer drugs have generally given some improvements,
there is a need for new drugs having mechanisms of action
different from those of the existing, established chemo-
therapeutics.
One such group of compounds are the aldehydes, some of
which were extracted as the active components of the essen-
tial oil of wintergreen, having antitumour effects in mice
without apparent side effects (Strong, 1936; 1939, see Tisse-
rand & Balacs, 1989 for a review). When several aldehydes
were screened for antitumour effects in mice (Boyland, 1940)
a few were shown to have significant antitumour effects at
doses less than 20% of the LD50 dose. Later citral and
citronellal (Osato, 1965) as well as derivatives of benzal-
dehyde (Kochi et al., 1980; 1985; 1988; 1990; Sakagami et al.,
1991) have been tested in clinical studies which are of con-
siderable interest although the design was not optimal. The
lack of a control group makes it difficult to evaluate the cure
rate, and the degree of effect is often weak and short-lasting
and even lacking in many of the patients. However, some
effects were found in most cancer types tested and no side-
effects were found in normal tissue. Thus, the effect of these
compounds appears to have been, to a great extent, specific
to cancer in the way such specificity was defined by Corbett
et al. (1987).
We have shown that the benzaldehyde derivatives act as
reversible protein synthesis inhibitors (Pettersen et al., 1983a;
1983b; 1985). This seems to be their primary cellular effect,
and, thus, cell inactivation follows only as a result of pro-
tracted inhibition of protein accumulation. A problem con-
cerning these drugs is, however, that their half-life in the
organism is relatively short (Pettersen et al., 1986; Borretzen
et al., 1989; Dornish et al., 1990). A continuous infusion is
impossible since the necessary treatment time could well be
several months. In a clinical phase II study on patients with
colon cancer (WHO performance status 2, life expectancy
> 3 months) given daily i.v. infusions with benzylidine-
glucose, we found essentially no clinical effect after 2 months
treatment, and it was difficult to motivate the clinicians for
longer treatment times (Tanum et al., 1990). Thus, there was
a need to synthesise new drugs with increased biological
effects, but without affecting the primary cellular mechan-
isms.
Recently, we have shown that deuteration of the formyl
group of benzaldehyde increases the cellular effect of this
compound in vitro (Pettersen et al., 1991a; B0rretzen et al.,
1989). Furthermore, in the compound zilascorb(2H) (see Pet-
tersen et al., 1991b) we used deuterated benzaldehyde to
synthesise an ascorbate acetal having stronger effects in vitro
than sodium benzylidene ascorbate (SBA) that was used by
Kochi et al. (1988). In the present study we have tested the
effect of zilascorb(2H) in two different human tumour xeno-
grafts grown in nude mice, a malignant melanoma (E.E.) and
an ovarian carcinoma (OVCAR-3). The effect was detected
both by means of tumour volume growth curves and by
means of histological evaluation of each separate tumour.
Materials and methods
Xenografts grown in nude mice
Two human xenografts were used in the present experiments,
one of malignant melanoma (E.E.) and one of ovarian car-
cinoma (OVCAR) origin. The E.E. melanoma xenograft was
originally derived from a lymph node metastasis in the left
axilla of a 62-year old man (Rofstad et al., 1977). The
volume doubling time of this tumour was 4.4 days (Rofstad,
1984). Tumour kinetic studies based on the method of 'per
cent labelled mitoses' and DNA flow cytometry (Rofstad et
al., 1980; Rofstad, 1984) have shown that the mean cell cycle
time was 41 h while the tumour growth fraction was in the
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range from 76 to 97% and the tumour cell loss in the range
from 33 to 52% (see Rofstad, 1984). The NIH:OVCAR-3
cell line, established by Hamilton et al. (1983) was purchased
from the American Tissue Culture Collection and cultivated
shortly in vitro before it was implanted into our nude mice.
Stable growth characteristics were obtained after the 4th
passage.
The tumours were implanted into female mice of the type
BALB/c/nu/nu/BOM bred at the animal house of The In-
stitute for Cancer Research, The Norwegian Radium Hos-
pital. The animal house is of a barrier type with strict
sterility control. The age of mice at the time of tumour
implantation was 9 weeks.
Drug treatment ofmice
Drug treatment was given by daily i.v. administration of
0.2 ml (in a 28 g mouse) saline (0.9% sodium chloride,
Travenol Laboratories, Halden, Norway) in a tail vein. The
first injection was given on the 12th day after tumour
implantation when the mean tumour volume was approxi-
mately 25 mm. Animals were routinely sacrificed when the
longest tumour diameter reached 20 mm. Treatment con-
tinued until the first animals had to be sacrificed according to
this criterium. This occurred 16 to 18 days after the first
treatment.
Tumour growth was followed by measuring two perpen-
dicular diameters using calipers (Uditest, Kraeplin Langen-
messgerat, Germany). Tumour volumes were calculated by
the formula V =lab2 where a is the longest and b is the
shortest diameter.
Morphological evaluation
All tumours were examined macroscopically and measured
before representative sections were taken. The macroscopic
examination included slicing of the tumour and a thorough
examination of the slices. Under the microscopic evaluation
the notes from the macroscopic observations were used as a
basis. On basis of both macroscopic and microscopic exam-
ination the extent of necrosis, obviously vital tumour nodules
as well as other morphological features were noted.
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Figure 1 Structure ofzilascorb(2H) as the sodium salt, indicating
the position of deuterium.
Two to 4 representative sections were taken from each
tumour and processed for light microscopy. The specimens
were fixed in 5% buffered formalin, dehydrated and embed-
ded in paraffin. Six to 8 glm thick sections cut from the
paraffin blocks were stained with haematoxylin and eosin,
and used for light microscopical evaluation. The micro-
scopical appearance was compared with the observations
made at the time of macroscopical examination and a semi-
quantitative evaluation of degree of tumour necrosis com-
pared to vital tumour tissue was made.
Drugs Zilascorb(2H) was produced at Norsk Hydro's Re-
search Center, Porsgrunn, Norway (B0rretzen et al., 1989).
The drug was injected as the sodium salt which is shown in
Figure 1.
Time after first injection (days)
Figure 2 Growth curves, by means of increase in tumour volume, for human melanoma tumours of the type E.E. grown as
xenografts in nude mice. The animals were treated with daily i.v. injections, in a tail vein, of zilascorb(2H) dissolved in isotonic salt
solution. Each group consisted of five animals, each having one tumour in the left flank. The curve representing animals treated
with salt solution only (placebo) is redrawn in each panel. Injections were given once daily. Day I represents the day of the first
injection. Tumour implantation took place 12 days before the first i.v. injection, i.e. on day 12.
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'H652 E.O. PETTERSEN et al.
Toxicity The LD50 dose of zilascorb(2H) in mice was found
to be approximately 2000 mg kg-' when given as a single
injection.
Results
Tumour volume growth curves of the E.E. melanoma xeno-
graft tumour grown in nude mice are shown in Figure 2.
Each of these growth curves represent the mean tumour
volume of 5 identically treated animals, each having one
tumour. The animals were given one i.v. injection daily of
isotonic saline containing zilascorb(2H) at doses as indicated
in each panel. Animals denoted 'placebo' were treated sim-
ilarly, but with saline without any zilascorb(2H). From the
volume growth curves as presented in this figure there is no
inhibition of tumour volume growth by a dose of 1 mgkg-'
of zilascorb(2H). Doses of 5 mgkg' as well as 20 mg kg'
induced a considerable inhibitory effect on the tumour
volume growth. This effect became apparent after 4 to 5 days
treatment.
To extend the dose scale to higher doses we also present
growth curves of a second experiment, including doses of 20
and 113 mg kg-' day-', in Figure 3.
Tumour volume growth curves of an experiment on
OVCAR-3 tumours including zilascorb(2H) doses of 20 and
40 mg kg-' day-' are shown in Figure 4. Although tumour
doubling times are longer for the OVCAR than for the E.E.
tumours the drug effect seem to be similar.
During treatment animal body weight was measured for
each animal once per week. In Table I mean body weight
values are shown for each group of the experiment represen-
ting OVCAR tumours.
All the volume growth curves shown in Figures 2, 3 and 4
were fitted by exponential functions in the time range above
5 days in order to determine tumour doubling times. From
these data, treatment with zilascorb(2H) at doses of 5 mg
kg- day-' and higher led to an increase in tumour volume
doubling times (Table II), while 1 mgkg-' gave no such
response.
To shed light on the question of whether the reduced
tumour volume growth rate is due to only growth inhibitory
effects or to cell inactivation, we have performed a mor-
phological examination of all tumours after the treatment
period. All animals were sacrificed the day after the last
treatment and a macroscopic as well as a microscopic
examination were done. The morphological appearances of
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Figure 3 A similar experiment to that described in the legend to
Figure 2, only with different drug doses.
Table I Mean body weight of animals treated with 20 or
40mgkg-' zilascorb(QH) by daily i.v. injections starting at day 1
Time after first injection (days)
Treatment 0 8 15 22
Placebo 23.7 ± 0.4 23.4 ± 0.5 23.6 ± 0.4 24.3 ± 0.4
20mg kg-' 23.7 ± 0.4 23.0 ± 0.4 23.4 ± 0.6 23.5 ± 0.9
40 mg kg-' 23.8± 0.4 23.5± 0.4 24.1 ± 0.4 25.3± 0.4
typical E.E. tumours from each of the four groups of animals
are shown in Figures 5-8. The same characteristics, present
in several experiments using protein synthesis inhibitors were
seen: While the necrotic areas in the placebo-treated tumours
are scattered as small spots throughout the tumours, the
drug-treated tumours often have a massive central necrotic
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Figure 4 A similar experiment to that described in the legend to Figure 2, only with ovarian carcinoma tumours of the type
OVCAR-3. Tumour implantation took place 28 days before the first i.v. injection.
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Table H Tumour volume doubling times of E.E. melanoma
tumours grown as xenografts in nude mice and treated daily with
zilascorb(2H) at drug doses as indicated. The data represent analysis
of the growth curves shown in Figure 6
Experiment Type of zilascorb('H) dose
number tumour (mgkg-'day-') TD± s.d.
E.E. Placebo 4.1 ± 0.2
1 malignant 1 3.7 + 0.2
melanoma 5 9.6± 1.1
20 7.4 0.2
E.E. Placebo 3.4 ± 0.2
2 malignant 20 9.6 1.0
melanoma 113 5.0 ± 0.4
OVCAR Placebo 10.8 ± 0.3
3 ovarian 20 19.0 0.6
carcinoma 40 19.2 ± 0.8
TD = tumour volume doubling time. s.d. = Standard deviation.
Figure 6 Zilascorb(QH) 1 mgkg-': Part of a tumour with exten-
sive necrosis. Only a peripheral rim with vital tumour tissue is
present (H/E x 35). Insert: High magnification of tumour cells
within the peripheral rim showing mitotic figures (H/E x 560).
Figure 5 Placebo group: Large tumour areas with only scattered
small necrotic foci as indicated by the arrows. (Haematoxylin and
eosin (H/E) x 35). Insert: High magnification of a transition
zone to necrotic cells (H/E x 700).
area, often including more than 70% of the tumour mass,
and surrounded by a layer of vital tumour tissue. Figure 7
shows an E.E. malignant melanoma tumour which decreased
in size during the 17 days of treatment with 5 mgkg-' day '
zilascorb(2H). Even in this very small tumour, measuring
only'-1Imm in diameter, the central region is completely
necrotic.
In some animals treated with zilascorb(2H), tumour nod-
ules with no sign of necrosis appeared. Typical examples of
this are shown in Figures 6 and 8. As indicated by the inserts
to these figures there are several mitotic figures in the areas
of vital tumour tissue.
The extent of necrosis has been estimated blindly for each
tumour and an overview of the estimates from experiments 1
and 3 are given in Table III. Analyses from this table
indicate a clear tendency of a higher fraction of necrotic
tissue in the tumours treated with 5 mg kg-' and 20 mg kg-'
zilascorb(2H) than in the placebo-treated tumours. In fact,
for the E.E. tumour, statistical testing of the difference
Figure 7 Zilascorb(2H) 5 mgkg-': Overview light microphoto-
graph of tumour with the extensive central necrotic area charac-
teristic to tumours after treatment with zilascorb(2H) (H/E x 28).
Insert: High magnification of necrotic cells in the center of the
tumour (H/E x 700).
between the placebo group and the two highest dose groups
concerning the number of tumours with more than 2 + gives
P = 0.026 (by Fisher's exact test). This finding should be
considered in light of the observation that the tumour
volumes were smaller for the drug-treated (i.e. 5 mg kg-' and654 E.O. PETTERSEN et al.
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Figure 8 Zilascorb(2H) 20 mgkg-': Parts of the necrotic tu-
mour. Note the nodules with proliferating tumour cells as
indicated by arrows (H/E x 35). Insert: High magnification of
tumour cells from the narrow rim in the periphery of the tumour
(H/E x 700).
Table III Histological evaluation of the amount of necrotic tissue in
the tumours after treatment (from experiments no 1 and 3)
Tumoura Number of animals
Treatment type 0 +b + + + + + + + + + Total
Placebo 0 1 4 0 0 5
lmgkg-' E:E. 0 0 4 1 0 5
Smg kg-' malignant 0 0 1 4 0 5
20 mg kg-' melanoma 0 0 2 3 0 5
Placebo OVCAR 1 3 1 0 0 5
20 mg kg-' ovarian 0 2 2 2 0 6
40 mg kg-' carcinoma 0 2 3 0 0 5
aThe i.v. injections were given daily for 17 days. bA semi-
quantitative evaluation of necrosis compared to vital tumour tissue
was made as follows: + =0-25% necrotic tumour volume;
+ + = 25-50% necrotic tumour volume; + + + = 50-75% necrotic
tumour volume; + + + + = 75-100% necrotic tumour volume.
20 mgkg-') than for the placebo-treated animals. Thus, the
drug-induced growth-inhibition demonstrated in Figure 2 is
due, mainly, to tumour cell inactivation and degeneration.
Since the protein synthesis inhibition induced by zila-
scorb(2H) was reversible in the in vitro cell system (Pettersen
et al., 1991b) it was important to see whether this was also
the case in the in vivo system. We therefore allowed the
tumours of the 20 mg kg-' group shown in Figure 3 to
continue growth after the end of the treatment. If the drug
acts in a truly reversible manner we would expect the tumour
to resume growth after treatment at the same rate as those
treated with placebo.
In Figure 9 the complete tumour volume growth curve is
shown together with that of the control. From these data, the
tumours quickly resume growth at a rate similar to that of
the placebo-treated tumours as soon as drug treatment stops.
Discussion
The main finding of the present paper is that protracted
treatment with zilascorb(2H) induces an antitumour effect in
Figure 9 Tumour volume growth curves of E.E. melanoma
tumour xenografts during and after daily treatment with 20 mg
kg-' zilascorb(2H).
two different human tumour xenografts. On basis of our
morphological studies of tumour necrosis, as indicated in
Table III and Figures 5 to 8, we conclude that zilascorb(2H)
treated tumours are more necrotic than placebo treated
tumours. We acknowledge the problem that our measure-
ment of the fraction of the tumour that is necrotic involves
elements of subjectivity and that our method do not extend
to the production of a stereological picture of the tumour.
However, taking into account the fact that the zilascorb(2H)
treated tumours have a much smaller volume than the
placebo treated tumours at the time of fixation we believe
this conclusion to be sound. Thus, the growth inhibition
demonstrated by the tumour volume growth curves of Fig-
ures 2, 3 and 4 to some extent underestimates the cellular
effect ofthe drug. Included in the volume ofthe zilascorb(2H)
treated tumours are drug-induced necrotic material that has
not, at the time of tumour fixation, been removed by the
vascular system of the tumour.
Comparing the effect of zilascorb(2H) here observed with
that observed by others using other benzaldehyde derivatives
in tumour bearing mice (Takeuchi et al., 1978; Taetle &
Howell, 1983) it seems that zilascorb(2H) is more effective. In
fact, experiments using various benzaldehyde derivatives
against tumours grown in mice have often shown little or no
effect, although the same derivatives were reported to be
effective in patients (Kochi et al., 1980; 1985; 1988; Tat-
semura, 1990). One can wonder whether this seeming
difference between the effect as seen in mice and in humans
could be due to some metabolic difference between the two
species, or perhaps, to differences in administration of the
drug, being i.v. injections in humans and i.p. injections in the
referred experiments in mice. Recently it has, however, been
shown that benzaldehyde, after i.p. administration as dis-
solved in fatty acids in mice inoculated with P388 leukaemia
cells, increased the animals life span with 50-100% (Bal-
azova & Koza, 1988), indicating that the duration of the
drug availability in the tumour is an important parameter
(B0rretzen et al., 1989).
Primary protein synthesis inhibition as apossible cause ofthe
antitumour effect
Zilascorb(2H) acts as a reversible protein synthesis inhibitor
in cultured cells (Pettersen et al., 1991b). While protein syn-TUMOUR NECROTISATION BY ZILASCORB(2H) 655
thesis was reduced immediately on addition of zilascorb(2H)
to the culture medium, cell inactivation appeared only after
extended treatment, and only at drug doses giving rise to
considerable reduction in the rate of protein accumulation.
The reversibility was most clearly demonstrated by our
finding that the few cells (0.7%) surviving a short treatment
of 10 h with a gigant dose of 10 mM zilascorb(2H), regained
completely normal growth rate immediately after ended treat-
ment (Pettersen et al., 1991b). Our in vitro studies, therefore,
point to protein synthesis inhibition as the cause of cell death
from zilascorb(2H). The antitumour effect appeared only
after more than 4 days of treatment (Figures 2, 3 and 4).
This is easily explained if one takes into consideration that a
mild protein synthesis inhibition might need to be imposed
on the cells for several days before the lack of vital proteins
become life threatening.
Zilascorb(2H) appears to have an unusual dose response
(Figures 2 and 3). While 1 mg kg-' day-' is obviously too
low a dose to result in a tumour effect in the E.E. malignant
melanoma xenograft, 5 mg kg-' day-' is high enough, and
higher doses do not seem to increase the response. Although
this finding is unusual as compared to most other drugs
tested for an antitumour effect, it is very much in line with
our findings concerning the protein synthesis inhibition in-
duced by zilascorb(2H) in cell cultures (Pettersen et al.,
1991b). In those cells, the rate of protein synthesis was
reduced to about 35% of its normal level at a drug concen-
tration of 1 mM, and could not be reduced much by a further
increase in drug concentration. Furthermore, from the data
of Figure 9, the antitumour effect of zilascorb(2H) is demon-
strated to be just as reversible as the protein synthesis inhibi-
tion induced in vitro (Pettersen et al., 1991b). Thus, this
accordance between protein synthesis inhibition in vitro and
tumour volume growth delay in vivo concerning both dose
response and reversibility indicate that inhibition of protein
synthesis is also in vivo the primary cellular effect of zila-
scorb(2H).
Lack ofside effects
In the present experiments, no signs of any side-effects were
seen in the animals, there was not observed any difference in
body weight between drug treated and placebo treated
animals (Table I) and there were no cellular destruction in
normal tissue. After as much as 18 or 24 days of treatment
with doses sufficient to induce tumour necrosis, this is strik-
ing, and indicates that normal cells are not only left intact by
the treatment, but are even able to keep up production of
vital enzymes to the organism. How can this be?
A hypothesis is that this could follow from the main
difference between cancer cells and their normal counterparts:
While cancer cells are not able to respond properly to
growth-regulatory stimuli, normal cells are. Although this is
recognised as the main difference between cancer and normal
cells, it is usually associated only with the observation that
cancer cells are unable to respond to down-regulatory sig-
nals. In other words, that cancer cells continue to proliferate
although the growth regulatory signals tell them to stop.
There is, however, to our knowledge no indication in the
literature that cancer cells respond more effectively to an
up-regulatory than to a down-regulatory signal. Thus, the
following hypothesis may explain the difference in response
to our protein synthesis inhibitor between normal and cancer
cells.
If a tumour-bearing animal is treated with a reversible
protein synthesis inhibitor, the treatment may induce a lack
of vital proteins, or a reduced rate of normal cell production
which, in turn, initiates up-regulatory or growth-stimulating
signals from the suffering tissues. These signals will be readily
understood by the normal cells which will have a reverse
capacity for protein synthesis and cell division to be acti-
vated. Most cancer cells, however, do not respond to the
growth-stimulating signals and are inhibited by the treat-
ment. If protein synthesis inhibition continues for a long
enough period of time the shortage of vital proteins may
become life-threatening to the cancer cells while normal cells
are left unharmed.
We know that the drugs tested in clinical studies by Dr
Kochi (1980, 1985, 1988), and later by others (Tatsemura et
al., 1990), induced some anticancer effect without any ob-
served side-effects and this is given an explanation with the
present hypothesis.
Warrington (1986) suggested that normal cells, as a res-
ponse to protein synthesis inhibition, will stop cycling while
cancer cells will not. In our opinion it is more likely that the
organism responds to reduced protein synthesis by enforcing
growth-stimulatory signals on the normal stem cells making
sure that the needs for necessary proteins and new cells are
satisfied. As far as we know there is no indication that cancer
cells have any special ability to continue growth in presence
of a protein synthesis inhibitor. Our view on this point is
strongly supported by our own earlier studies concerning the
relation between cell cycling and protein accumulation of
cancer cells in vitro. Using either cycloheximide (R0nning et
al., 1981) or benzaldehyde (Pettersen et al., 1983a,b) to
induce a reversible protein synthesis inhibition, we found that
a time-limited protein synthesis inhibition slowed down the
rate of cell-cycle progression in all stages of interphase. Fur-
thermore, in the absence of protein accumulation, cell div-
ision did not take place (R0nning et al., 1981) although there
was still some cell-cycle progression (R0nning & Lindmo,
1983; R0nning & Pettersen, 1984).
The present hypothesis presents a possibility to develop
new, cancer-specific chemical agents. However, it is little
known about the degree of effect on the tumour that may
come out of such a treatment. Basically we have no guar-
antee that a chemically induced effect in a tumour, although
specific to the tumour, would be very strong, or even involve
inactivation of cancer cells. However, even a growth inhibi-
tion, if it is induced in the tumour only, may give a
significant contribution in the treatment of many cancer
patients. The present treatment, although not able to remove
all cancer cells in any of the treated animals over an 18 or 24
days period, seems to have inactivated, and not just inhi-
bited, cancer cells.
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